Stereotaxis is trading at $1.09, up 7.01% in pre-market; no confirmed catalyst was identified. - No new company announcement was identified for October 26. The latest news, on October 22, said Latvia’s Pauls Stradiņš Clinical University Hospital installed Genesis and began treating patients, creating the country’s first robotic arrhythmia-treatment program. The news preceded the move, so a direct link is unconfirmed. - Third-quarter results are scheduled for November 10, not October 26. Major U.S. indices were little changed in the supplied market context, offering no clear broad-market explanation.